R
RenovoRx, Inc. (RNXT)
NCM – Real vaqt narxi. Valyuta: USD
1.13
-0.03 (-2.59%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
1.16
+0.03 (2.65%)
Bozordan keyin: Mar 27, 2026, 7:47 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NCM – Real vaqt narxi. Valyuta: USD
1.13
-0.03 (-2.59%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
1.16
+0.03 (2.65%)
Bozordan keyin: Mar 27, 2026, 7:47 PM EDT
RenovoRx, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, saraton kasalligi bilan og'rigan bemorlarning davolash natijalarini yaxshilash uchun maqsadli kombinatsiyalangan terapiyalarni ishlab chiqish bilan shug'ullanadi. Uning asosiy mahsulot nomzodi gemtsitabin kimyoterapiyasi bo'lib, u RenovoCath orqali taqdim etiladi va mahalliy rivojlangan oshqozon osti bezi saratonini davolash uchun III bosqich klinik sinovlarida. RenovoRx, Inc. 2009-yilda tashkil etilgan va shtab-kvartirasi Mountain View, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Ramtin Agah M.D. | Founder, Chairman of Board & Chief Medical Officer |
| Mr. Mark Voll | CFO & Principal Accounting Officer |
| Mr. Robert Strasser | Vice President of Operations and R&D |
| Mr. Ronald B. Kocak CPA, CGMA | VP of Finance & Controller |
| Mr. Ryan Witt | Senior VP and Head of Corporate Strategy & Partnerships |
| Mr. Shaun R. Bagai | CEO, Secretary & Director |
| Ms. Leesa Gentry | Chief Clinical Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-02 | 8-K | form8-k.htm |
| 2025-11-14 | 8-K | form8-k.htm |
| 2025-11-13 | 10-Q | form10-q.htm |
| 2025-08-14 | 10-Q | form10-q.htm |
| 2025-08-13 | CORRESP | filename1.htm |
| 2025-07-18 | CORRESP | filename1.htm |
| 2025-06-27 | S-8 | forms-8.htm |
| 2025-06-25 | 8-K | form8-k.htm |
| 2025-05-15 | 8-K | form8-k.htm |
| 2025-04-30 | DEF 14A | formdef14a.htm |